Renaissance Capital logo

mapi News

Israeli drug developer Mapi-Pharma officially withdraws $50 million US IPO

Mapi-Pharma, which is developing extended-release formulations of existing drugs and generics, officially withdrew its plans for an initial public offering on Monday. The company originally filed to raise $40 million in an April 2014 IPO, postponed the offering, re-launched a $50 million IPO in January 2016, and again postponed. The Ness Ziona, Israel-based company was founded...read more

Week ahead: IPO market still stuck in neutral

SNDX

The IPO market remains in the doldrums this week, but the Renaissance IPO Index's 10% gain in the past two weeks suggests that the IPO train could start rolling again in March. Second time's a charm After a scrapped IPO attempt in June 2014, Syndax Pharmaceuticals (SNDX) has shifted its business focus after discovering new indications for its...read more

Week ahead: A microcap biotech and a SPAC

INTR

The IPO market continued at its snail's pace with only two pricing dates set and one initial filing for an up-listing this past week. The slowdown is to be expected around this time of year as companies update their year-end financials. Papa's special Silver Run Acquisition (SRAQU), a blank check company formed by Mark Papa and...read more

Week ahead: Biotechs could snap IPO drought

EDIT

February is kicking off with four potential biotech pricings, including heavy hitters Editas Medicine and BeiGene. These two IPOs could breathe life back into the IPO market after a deal-less January and a sharp decline in the Nasdaq Biotech Index (down 21% YTD). CRISPR’s public markets debut Early-stage biotech Editas Medicine (EDIT) represents the...read more